# ![@IntensityInc Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1149150774.png) @IntensityInc Intensity Therapeutics

Intensity Therapeutics posts on X about $ints, ceo, in the, we are the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1149150774/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1149150774/c:line/m:interactions.svg)

- [--] Week [-----] -29%
- [--] Month [------] +126%
- [--] Months [------] +127%

### Mentions: [--] [#](/creator/twitter::1149150774/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1149150774/c:line/m:posts_active.svg)

- [--] Months [--] +125%

### Followers: [---] [#](/creator/twitter::1149150774/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1149150774/c:line/m:followers.svg)

- [--] Week [---] +0.10%
- [--] Month [---] +1%
- [--] Months [---] +48%

### CreatorRank: [---------] [#](/creator/twitter::1149150774/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1149150774/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  97.5% [finance](/list/finance)  9.17% [ncaa football](/list/ncaa-football)  3.33% [countries](/list/countries)  2.5% [exchanges](/list/exchanges)  1.67% [social networks](/list/social-networks)  1.67% [technology brands](/list/technology-brands)  1.67% [financial services](/list/financial-services)  #2609

**Social topic influence**
[$ints](/topic/$ints) #2, [ceo](/topic/ceo) 18.33%, [in the](/topic/in-the) 6.67%, [we are](/topic/we-are) 5%, [investment](/topic/investment) 3.33%, [check](/topic/check) 3.33%, [target](/topic/target) 2.5%, [data](/topic/data) 2.5%, [release](/topic/release) 2.5%, [science](/topic/science) 2.5%

**Top accounts mentioned or mentioned by**
[@ebiomedicine](/creator/undefined) [@asco](/creator/undefined) [@sabcssanantonio](/creator/undefined) [@lewbender](/creator/undefined) [@drelkhoueiry](/creator/undefined) [@americancancer](/creator/undefined) [@pharmaphorum](/creator/undefined) [@progresspotent1](/creator/undefined) [@valiantceo](/creator/undefined) [@ctosociety](/creator/undefined) [@nasdaq](/creator/undefined) [@pharmasalmanacs](/creator/undefined) [@clinicalleader1](/creator/undefined) [@jpmorg](/creator/undefined) [@irat1onal](/creator/undefined) [@youtube](/creator/undefined) [@coreir](/creator/undefined) [@rarediseaseday](/creator/undefined) [@edclinical](/creator/undefined) [@hcwcos](/creator/undefined)

**Top assets mentioned**
[Intensity Therapeutics, Inc. (INTS)](/topic/$ints)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$INTS is proud to have our VP of Clinical Operations Kimberly Guedes featured as a keynote presenter at the COG Bay Area conference kicking off today. Shell discuss how stakeholder collaboration accelerates #clinicaltrials drives innovation & operational excellence"  
[X Link](https://x.com/IntensityInc/status/1980611462872641620)  2025-10-21T12:25Z [---] followers, [----] engagements


"In a new Q&A with @ValiantCEO_ #IntensityTherapeutics' CEO Lew Bender shares how $INTS evolved from a basement startup to a late-stage biotech listed on Nasdaq that is advancing its first-in-class #cancer therapies including INT230-6. Full Q&A: #INTS https://bit.ly/3Jz9ylp https://bit.ly/3Jz9ylp"  
[X Link](https://x.com/IntensityInc/status/1983148815356940653)  2025-10-28T12:28Z [---] followers, [----] engagements


"$INTS Phase 1/2 of INT230-6 shows safety & efficacy in metastatic/refractory cancers. 40% tumor burden dosing: 83% disease control 18.7-mo median OS & 20% abscopal effects. @DrElkhoueiry highlights local & systemic potential. @eBioMedicine paper: https://bit.ly/3LdqWg2 https://bit.ly/3LdqWg2"  
[X Link](https://x.com/IntensityInc/status/1985372516127228127)  2025-11-03T15:44Z [---] followers, [----] engagements


"#INTS study published in @eBioMedicine shows #INT2306 was well tolerated & demonstrated antitumor activity immune activation & abscopal effects. The results support $INTS' approach to treating injected & noninjected tumors. Full paper: #eBioMedicine https://bit.ly/3LdqWg2 https://bit.ly/3LdqWg2"  
[X Link](https://x.com/IntensityInc/status/1986069441617010733)  2025-11-05T13:53Z [---] followers, [----] engagements


"#IntensityTherapeutics Phase 1/2 study shows INT230-6 has predictable dose response plasma exposure for cisplatin vinblastine and SHAO across dose volumes from [--] to [---] mL indicating 95% of the active agents remain in the tumor and supporting controlled consistent delivery resulting in a favorable safety profile. Read more: $INTS #Oncology http://bit.ly/3LdqWg2 http://bit.ly/3LdqWg2"  
[X Link](https://x.com/IntensityInc/status/1990511820411674661)  2025-11-17T20:06Z [---] followers, [----] engagements


"#IntensityTherapeutics had a great time at the @ctosociety annual meeting with a large number of our Phase [--] investigators who are advancing care for rare and hard-to-treat #sarcomas. $INTS appreciated the chance to engage with other researchers clinicians & partners as we continue progressing #INT2306. #CTOS2025 https://twitter.com/i/web/status/1990791365710520723 https://twitter.com/i/web/status/1990791365710520723"  
[X Link](https://x.com/IntensityInc/status/1990791365710520723)  2025-11-18T14:37Z [---] followers, [----] engagements


"Immunohistochemistry (IHC) results following two #INT230-6 doses in the Phase 1/2 study show T-cell infiltration in a sarcoma patients tumor compared to the pre-dose biopsy. Seen in 13/14 matched pair biopsies supporting proof-of-concept for immune activation in tumors. Read the full study: $INTS #eBioMedicine http://bit.ly/3LdqWg2 http://bit.ly/3LdqWg2"  
[X Link](https://x.com/IntensityInc/status/1991213682827972985)  2025-11-19T18:35Z [---] followers, [----] engagements


"#IntensityTherapeutics' CEO Lew Bender discusses the challenges of current neoadjuvant regimens and how #INT2306 could offer a more targeted less toxic approach for women with #TNBC. Read the full feature via #DrugDiscovery: $INTS #CancerResearch https://bit.ly/4hOkLew https://bit.ly/4hOkLew"  
[X Link](https://x.com/IntensityInc/status/1991501665346965547)  2025-11-20T13:39Z [---] followers, [----] engagements


"$INTS Study IT-01 first author Jacob S. Thomas M.D. highlights the #INT230-6s dual potential to target tumors and activate the immune system. Phase 1/2 data show promising efficacy and favorable safety in advanced #metastaticcancers. Full study: http://bit.ly/3LdqWg2 http://bit.ly/3LdqWg2"  
[X Link](https://x.com/IntensityInc/status/1992955392322679233)  2025-11-24T13:56Z [---] followers, [----] engagements


"New data from #IntensityTherapeutics Phase 1/2 study show encouraging efficacy and survival with INT230-6 in advanced #cancers. A novel intratumoral therapy designed to target tumors and activate the immune system. Learn more: $INTS http://bit.ly/3LdqWg2 http://bit.ly/3LdqWg2"  
[X Link](https://x.com/IntensityInc/status/1993315949395820708)  2025-11-25T13:48Z [---] followers, [----] engagements


"Cancer survival rates are expected to rise over the next decade per @AmericanCancer #IntensityTherapeutics is working to support this progress as we advance #INT2306 & its potential to improve patient outcomes. Learn more about $INTS' innovative work: https://bit.ly/47qAopx https://bit.ly/47qAopx"  
[X Link](https://x.com/IntensityInc/status/1995851735768989795)  2025-12-02T13:45Z [---] followers, [----] engagements


"#IntensityTherapeutics will present two presentations at @SABCSSanAntonio [----] highlighting the Companys advancing pipeline and #INT2306s potential in #breastcancer including early-stage #TNBC. Full release: $INTS #SABCS25 https://bit.ly/4pj1zst https://bit.ly/4pj1zst"  
[X Link](https://x.com/IntensityInc/status/1996573570189705363)  2025-12-04T13:33Z [---] followers, [----] engagements


"#IntensityTherapeutics received a 180-day extension from @Nasdaq to regain compliance with the $1.00 minimum bid requirement. There is no immediate impact on the Companys listing and $INTS will continue trading on the #Nasdaq Capital Market. Full PR: https://bit.ly/4pkrD6i https://bit.ly/4pkrD6i"  
[X Link](https://x.com/IntensityInc/status/1996941623847268594)  2025-12-05T13:55Z [---] followers, [----] engagements


"Lew Bender CEO of #IntensityTherapeutics joined the @pharmaphorum Podcast to discuss how intra-tumoural therapies can kill tumors and trigger an immune response within days including in cancers that do not respond to #immunotherapy. Full episode: $INTS https://bit.ly/4rS4n1t https://bit.ly/4rS4n1t https://bit.ly/4rS4n1t https://bit.ly/4rS4n1t"  
[X Link](https://x.com/IntensityInc/status/1998389728459030613)  2025-12-09T13:50Z [---] followers, [----] engagements


"$INTS is presenting two posters at @SABCSSanAntonio. PS5-08-16 shares early Ph2 INVINCIBLE [--] #TNBC data showing favorable safety with #INT2306 patients reporting 50% fewer grade 3+ adverse events vs standard neoadjuvant chemo. PS4-10-15 outlines a potential Ph3 study design with and without doxorubicin. PR: #SABCS25 https://bit.ly/4rOhhNE https://bit.ly/4rOhhNE"  
[X Link](https://x.com/IntensityInc/status/1999111537680621837)  2025-12-11T13:38Z [---] followers, [----] engagements


"#IntensityTherapeutics had a great week at @SABCSSanAntonio (#SABCS25) connecting with the #breastcancercommunity. CEO Lew Bender CMO Ian Walters and Dr. Andreas Mueller were onsite with our INVINCIBLE-4 poster sharing our latest work to advance #cancercare. $INTS"  
[X Link](https://x.com/IntensityInc/status/2000921354837635444)  2025-12-16T13:30Z [---] followers, [----] engagements


"#IntensityTherapeutics' CEO Lew Bender joins @pharmasalmanac's December roundtable to discuss the rise of #GLP1 therapies and their impact on the pharmaceutical landscape. Read the full roundtable: $INTS https://bit.ly/3YkGNfT https://bit.ly/3YkGNfT"  
[X Link](https://x.com/IntensityInc/status/2001646128639418582)  2025-12-18T13:30Z [---] followers, [----] engagements


"Happy Holidays from the #IntensityTherapeutics team Heres to a joyful season and a healthy year ahead. #INTS #HappyHolidays"  
[X Link](https://x.com/IntensityInc/status/2003458070677250224)  2025-12-23T13:30Z [---] followers, [----] engagements


"In a new expert discussion from @ClinicalLeader1 industry leaders agree that statistical significance alone isnt enough for real patient benefit. Lew Bender CEO of $INTS explains why clinically meaningful endpoints matter. Read the full POV: #INTS https://bit.ly/44UdkNQ https://bit.ly/44UdkNQ"  
[X Link](https://x.com/IntensityInc/status/2008535194794414240)  2026-01-06T13:44Z [---] followers, [----] engagements


"$INTS' CEO Lew Bender explains in #DrugDiscovery Online how INT230-6s intratumoral approach may offer a safer more effective alternative to current neoadjuvant regimens for women with early #breastcancer & #TNBC. Read the full feature: #Oncology https://bit.ly/4hOkLew https://bit.ly/4hOkLew"  
[X Link](https://x.com/IntensityInc/status/2009269906647273501)  2026-01-08T14:24Z [---] followers, [----] engagements


"#DfuseRxSM is #IntensityTherapeutics' proprietary technology that delivers drug compounds directly into #solidtumors with high absorption. Patented dispersion and cell penetration molecules enable targeted safer dosing. Learn more: $INTS #INTS #BioTech http://bit.ly/3GYhlaF http://bit.ly/3GYhlaF"  
[X Link](https://x.com/IntensityInc/status/2011792988834578939)  2026-01-15T13:30Z [---] followers, [----] engagements


"Last week the $INTS leadership team attended the @jpmorg Healthcare Conference in San Francisco where they connected with healthcare investment bankers analysts potential strategic pharma partners and industry peers. #JPM2026 #JPM26"  
[X Link](https://x.com/IntensityInc/status/2013604928527442125)  2026-01-20T13:30Z [---] followers, [----] engagements


"#IntensityTherapeutics delivered meaningful clinical and corporate progress in [----] including continued advancement of the INVINCIBLE-4 Phase [--] study and peer-reviewed validation of #INT2306. Read more: $INTS #ClinicalResearch https://bit.ly/4qIBe7a https://bit.ly/4qIBe7a"  
[X Link](https://x.com/IntensityInc/status/2014329705013604751)  2026-01-22T13:30Z [---] followers, [----] engagements


"$INTS' CEO Lew Bender joined @irat1onal on the Progress Potential and Possibilities podcast to discuss #Intensitys intratumoral approach and the science behind #INT2306. Watch or listen to the full episode on @YouTube: https://bit.ly/4pP9pJP Turning Tumors Into Their Own Immunotherapies - Lewis Bender - @LewBender - CEO Intensity Therapeutics - @IntensityInc @CoreIR_ @ProgressPotent1 @irat1onal #Intratumoral #Immunotherapy #NeoantigenRelease #AdaptiveImmuneResponse https://t.co/So5rvl3ty3 https://t.co/D6SRMmD690 https://bit.ly/4pP9pJP Turning Tumors Into Their Own Immunotherapies - Lewis"  
[X Link](https://x.com/IntensityInc/status/2016141643402117146)  2026-01-27T13:30Z [---] followers, [----] engagements


"#ICYMI: Lew Bender CEO of $INTS shared insights on #Intensitys intratumoral approach and the differentiation of INT230-6 in a feature with Drug Development & Delivery. Full feature: #INT2306 #CancerResearch https://bit.ly/4q0K0Ot https://bit.ly/4q0K0Ot"  
[X Link](https://x.com/IntensityInc/status/2016866417878941730)  2026-01-29T13:30Z [---] followers, [---] engagements


"On a recent @pharmaphorum Podcast Lew Bender CEO of #IntensityTherapeutics shared clinical observations from the INT230-6 Phase 1/2 trial including encouraging outcomes in #sarcoma that supported the move into Phase [--]. Catch up on the full episode: $INTS #ClinicalTrials https://bit.ly/4rS4n1t https://bit.ly/4rS4n1t"  
[X Link](https://x.com/IntensityInc/status/2018678361615126557)  2026-02-03T13:30Z [---] followers, [---] engagements


"This #WorldCancerDay we stand with patients families and caregivers impacted by cancer worldwide. $INTS is advancing a novel intratumoral approach designed to target tumors and activate the immune response to help improve outcomes across #solidtumors. #CancerAwareness"  
[X Link](https://x.com/IntensityInc/status/2019040747518087600)  2026-02-04T13:30Z [---] followers, [---] engagements


"Our drug INT230-6 was designed specifically to treat pancreatic cancer"  
[X Link](https://x.com/IntensityInc/status/1030196281765900288)  2018-08-16T20:55Z [---] followers, [--] engagements


"We are another day closer to presenting our latest results at ESMO which is being held in Munich October 19-23"  
[X Link](https://x.com/IntensityInc/status/1049388562595033091)  2018-10-08T19:58Z [---] followers, [--] engagements


"We are at the JP Morgan Healthcare conference. Our investor relations firm scheduled [--] meetings for the next [--] days. This week we have meetings with pharmaceutical companies investment bankers investors and analysts"  
[X Link](https://x.com/IntensityInc/status/1082737021808852992)  2019-01-08T20:33Z [---] followers, [--] engagements


"Day [--] and [--] of the Healthcare Industrys equivalent of Burning Man in San Francisco known as the JP Morgan Conference the Company had over [--] meetings with investors pharmaceutical companies (domestic and foreign) analysts and bankers"  
[X Link](https://x.com/IntensityInc/status/1083088737012043777)  2019-01-09T19:50Z [---] followers, [--] engagements


"January was an extremely busy month for @IntensityInc which is why our tweet productivity was way down. We are working on a number of excellent opportunities. Stay tuned"  
[X Link](https://x.com/IntensityInc/status/1091435104184889344)  2019-02-01T20:36Z [---] followers, [--] engagements


"Thursday is @rarediseaseday. Intensity is honored to have had the opportunity to treat patients with two types of rare cancers cholangiocarcinoma aka bile duct cancer and chordoma through our ongoing Phase 1/2 clinical study of INT230-6"  
[X Link](https://x.com/IntensityInc/status/1100850514726506496)  2019-02-27T20:09Z [---] followers, [--] engagements


"To date our ongoing Phase 1/2 trial has treated patients with more than [--] different types of advanced solid tumors including breast cancer and we look forward to evaluating use of INT230-6 in other areas for potential registration-enabling studies"  
[X Link](https://x.com/IntensityInc/status/1118966983838568452)  2019-04-18T19:58Z [---] followers, [--] engagements


"Intensity is proud to be selected to present our latest findings in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting on June [--] [----] 8-11 AM CDT represented by Jacob Stephen Thomas MD from USC. https://bit.ly/2LNwOxy https://bit.ly/2LNwOxy"  
[X Link](https://x.com/IntensityInc/status/1129339536578736128)  2019-05-17T10:55Z [---] followers, [--] engagements


"The @IntensityInc poster will be presented at #ASCO19 on Saturday June [--] by Dr. Anthony El-Khoueiry from USC and our team from 8AM to 11AM CDT. The safety profile and data on immune activation will be shown. https://bit.ly/2XbIFXg https://bit.ly/2XbIFXg"  
[X Link](https://x.com/IntensityInc/status/1134185718778138624)  2019-05-30T19:52Z [---] followers, [--] engagements


"INT230-6 shows promise highlighting the results from [--] patients with [--] different types of advanced or metastatic solid tumors that have failed approved available therapies. https://bit.ly/2WJtQ17 https://bit.ly/2WJtQ17"  
[X Link](https://x.com/IntensityInc/status/1135596737270288385)  2019-06-03T17:18Z [---] followers, [--] engagements


"Intensity Therapeutics INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology. INT230-6 shows ability to regress tumors and initiate a T cell mediated systemic immune response against cancer. https://bit.ly/2XUEoa7 https://bit.ly/2XUEoa7"  
[X Link](https://x.com/anyuser/status/1151790609306464256)  2019-07-18T09:47Z [---] followers, [--] engagements


""I am humbled by being selected by PharmaVOICE as one its [---] most inspiring people in life sciences and grateful for being given the chance to try and help patients with cancer." Lew Bender [----] #PharmaVOICE100 Lewis Bender CEO Intensity Therapeutics invented a treatment to help the immune system identify cancer cells-with no experience in research or cancer. Start-in-the-basement story he founded @IntensityInc in [----]. #pharma #leadership https://t.co/eASfg50OwP https://t.co/EF7gHDAkMh [----] #PharmaVOICE100 Lewis Bender CEO Intensity Therapeutics invented a treatment to help the immune"  
[X Link](https://x.com/anyuser/status/1158470961336918016)  2019-08-05T20:12Z [---] followers, [--] engagements


"Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Mercks Keytruda https://bwnews.pr/2JGqBjn https://bwnews.pr/2JGqBjn"  
[X Link](https://x.com/anyuser/status/1190371780365451264)  2019-11-01T20:55Z [---] followers, [--] engagements


"Intensity is proud to announce we have treated our first patient with our drug INT230-6 in combination with Merck's Keytruda. We continue to seek to understand the effectiveness of our drug alone and in combination with other drugs in clinical trials. https://bwnews.pr/2NS1L1p https://bwnews.pr/2NS1L1p"  
[X Link](https://x.com/IntensityInc/status/1191461406035439617)  2019-11-04T21:05Z [---] followers, [--] engagements


"Our study included a highly refractory patient population nonetheless several patients have had long term benefit. The treatment is well tolerated and no patients had to discontinue therapy due to treatment-related toxicity. -Jacob Thomas MD Presenter"  
[X Link](https://x.com/IntensityInc/status/1194006522654650369)  2019-11-11T21:38Z [---] followers, [--] engagements


"In patients that had over [--] percent of total tumor burden injected seven out of eight patients have shown disease control including all four patients enrolled with metastatic breast cancer. The treatment is well-tolerated. -Jacob Thomas MD presenter"  
[X Link](https://x.com/IntensityInc/status/1194035276609249280)  2019-11-11T23:32Z [---] followers, [--] engagements


"Lewis H. Bender Founder & CEO of Intensity Therapeutics discusses the future of cancer research with Charlene Liao CEO of Immune-Onc at the East/West CEO meetings Developments in the Oncology Landscape panel on Sunday January 12"  
[X Link](https://x.com/IntensityInc/status/1218290035075633152)  2020-01-17T21:52Z [---] followers, [--] engagements


"Intensity Therapeutics made the front page of Clinical Leader for our innovative method of treating cancer. Thank you @EdClinical for the interview and for your thoughtful article on our cancer treatment process. https://bit.ly/2U2kL1e https://bit.ly/2U2kL1e"  
[X Link](https://x.com/anyuser/status/1241044152504037376)  2020-03-20T16:49Z [---] followers, [--] engagements


"Intensity Therapeutics is quite pleased that our research was recognized by our scientific peers to merit publication in the prestigious International Journal of Molecular Sciences. http://doi.org/10.3390/ijms21124493 http://doi.org/10.3390/ijms21124493"  
[X Link](https://x.com/IntensityInc/status/1276243047164948481)  2020-06-25T19:57Z [---] followers, [--] engagements


"Bringing INT230-6 into phase [--] human testing in combination with Keytruda is another major milestone for Intensity Therapeutics -Lew Bender CEO"  
[X Link](https://x.com/IntensityInc/status/1304152526132920320)  2020-09-10T20:19Z [---] followers, [--] engagements


"Intensity Therapeutics' drug INT230-6 is being tested in combination with #Keytruda in a phase [--] study to fight PC"  
[X Link](https://x.com/IntensityInc/status/1325927467001868290)  2020-11-09T22:25Z [---] followers, [--] engagements


"The patent will last until September [--] [----] and completes our coverage in North America"  
[X Link](https://x.com/IntensityInc/status/1349768517780975618)  2021-01-14T17:21Z [---] followers, [--] engagements


"#Intratumoral delivery requires an understanding of the chemistry required for tumor and cancer cellular absorption post-injection which is why INT230-6 has so far shown positive results in clinical testing where others have failed"  
[X Link](https://x.com/IntensityInc/status/1359158326131580929)  2021-02-09T15:12Z [---] followers, [--] engagements


"@IntensityInc clinical investigators are making two presentations at the [----] @ASCO Annual Meeting of new data from our ongoing trial testing INT230-6 in metastatic refractory #SolidTumor #cancer. #ASCO21 is taking place virtually June 4-8. Details here: https://bit.ly/3hFvxqp https://bit.ly/3hFvxqp"  
[X Link](https://x.com/IntensityInc/status/1395373550572298240)  2021-05-20T13:39Z [---] followers, [--] engagements


"#POTUS spoke tonight about cutting deaths from #CANCER new technologies such as those of @IntensityInc are able to do so"  
[X Link](https://x.com/IntensityInc/status/1498859600514371584)  2022-03-02T03:15Z [---] followers, [--] engagements


"At #ASCO22 three @IntensityInc abstacts were selected for [--] poster and [--] podium discussion session. Data in #sarcoma and #breastcancer for INT230-6 alone and in other #Cancers combined with Keytruda and INT230-6 with Yervoy were shown"  
[X Link](https://x.com/IntensityInc/status/1533928408614313985)  2022-06-06T21:46Z [---] followers, [--] engagements


"#IntensityTherapeutics will attend @HCWCO's 27th Annual Global Investment Conference Sept 8-10 at @lottenypalace. CEO Lew Bender will join Dr. Swayampakula Ramakanth for a fireside chat available on demand Sept [--] at 7am ET. Full release: $INTS #HCW http://bit.ly/4p0LHLc http://bit.ly/4p0LHLc"  
[X Link](https://x.com/anyuser/status/1962853175037227506)  2025-09-02T12:20Z [---] followers, [----] engagements


"New imaging from #IntensityTherapeutics #INVINCIBLE4 trial shows tumor necrosis after two doses of INT230-6 prior to standard-of-care. The first treated patient achieved a complete pathological response. Learn more about $INTS' clinical research: #TNBC https://bit.ly/40ipTjJ https://bit.ly/40ipTjJ"  
[X Link](https://x.com/anyuser/status/1970467274155860269)  2025-09-23T12:36Z [---] followers, [----] engagements


"Check out this article from @pharmasalmanac on making rare disease drug development sustainable. $INTS CEO Lew Bender explains why aligning science trials finance & regulation with early stakeholder collaboration is key to delivering #therapies. https://bit.ly/4pIe7u1 https://bit.ly/4pIe7u1"  
[X Link](https://x.com/anyuser/status/1973002050587046038)  2025-09-30T12:28Z [---] followers, [----] engagements


"#IntensityTherapeutics is excited to attend @avbcancercare's Cancer Research & Innovation Symposium on Oct [--] in NY. CEO Lew Bender will join the Blueprint for Emerging Start-ups panel at 9:30am ET to share insights on funding pitching & early-stage growth. #GCRIS2025"  
[X Link](https://x.com/anyuser/status/1979166443871633431)  2025-10-17T12:43Z [---] followers, [---] engagements


"$INTS has entered into a securities purchase agreement with a new long-term fundamental investor for the purchase and sale of [--] million shares of common stock at a purchase price of $0.80 per share for gross proceeds of about $4 million. Read more: https://bit.ly/433Sr1Q https://bit.ly/433Sr1Q"  
[X Link](https://x.com/anyuser/status/1984230672740048985)  2025-10-31T12:07Z [---] followers, [----] engagements


"#IntensityTherapeutics highlights how INT230-6 targets tumors & activates immune cells. Phase 1/2 data in @eBioMedicine show intratumoral dosing triggers T-cell infiltration abscopal effects & improved disease control. Read the full manuscript: $INTS https://bit.ly/3LdqWg2 https://bit.ly/3LdqWg2"  
[X Link](https://x.com/anyuser/status/1985710163983028386)  2025-11-04T14:06Z [---] followers, [----] engagements


"#IntensityTherapeutics reports Q3 [----] financial results & a corporate update. #INTS plans to file a protocol amendment in the #INVINCIBLE4 study to revise dosing & reinitiate enrollment in Q1 [----]. With recent capital raises $INTS' cash runway now extends through Q1 [----]. Full release: #INT2306 #ClinicalTrials https://bit.ly/3Lq1WCm https://bit.ly/3Lq1WCm"  
[X Link](https://x.com/anyuser/status/1986541989878530303)  2025-11-06T21:11Z [---] followers, [----] engagements


"Check out this interview in @afurtherinquiry on $INTS' intratumoral therapy #INT2306. CEO Lew Bender explains how INT230-6 is redefining #cancertreatment the science behind #DfuseRx and insights from ongoing #clinicaltrials. Read more: https://bit.ly/4hFlqim https://bit.ly/4hFlqim"  
[X Link](https://x.com/anyuser/status/1987880081780347193)  2025-11-10T13:48Z [---] followers, [----] engagements


"Kaplan-Meier data from #IntensityTherapeutics INT230-6 study shows improved survival in advanced #sarcoma. In a heavily pretreated sarcoma patient population using intratumoral INT230-6 alone the median overall survival (mOS)was [----] months. Patients dosed at 40% of their total tumor burden had not yet reached mOS compared to [---] months for those dosed 40%. See more: $INTS http://bit.ly/3LdqWg2 http://bit.ly/3LdqWg2"  
[X Link](https://x.com/anyuser/status/1988241520902672490)  2025-11-11T13:44Z [---] followers, [----] engagements


"$INTS Phase 1/2 study shows haematoxylin & eosin staining of a biopsy from a patient with liposarcoma. Darker areas show cancer cells lighter areas show tumor necrosis. [--] of [--] matched-pair biopsies showed similar patterns. Full @eBioMedicine paper: http://bit.ly/3LdqWg2 http://bit.ly/3LdqWg2"  
[X Link](https://x.com/anyuser/status/1988961769206034628)  2025-11-13T13:26Z [---] followers, [----] engagements


"$INTS shares [----] milestones and outlines [----] priorities reflecting progress across clinical scientific and financial execution. Highlights include peer-reviewed clinical validation of #INT2306 in @eBioMedicine and an operational runway into [----]. Full PR: https://bit.ly/4qIBe7a https://bit.ly/4qIBe7a"  
[X Link](https://x.com/anyuser/status/2011070621690552791)  2026-01-13T13:39Z [---] followers, [----] engagements


"#Breastcancer continues to impact hundreds of thousands with @AmericanCancer estimating over [------] new invasive cases in the U.S. in [----]. $INTS is advancing #INT2306 to activate the immune system and improve patient outcomes. Learn more: https://bit.ly/40ipTjJ https://bit.ly/40ipTjJ"  
[X Link](https://x.com/IntensityInc/status/2021215072891060673)  2026-02-10T13:30Z [---] followers, [---] engagements


"Ovarian cancer survivor told she only had [--] months to live is thriving [--] years later. There is hope. Intensity has treated ovarian cancer patients with no drug related systemic toxicity. https://bit.ly/2nUW5Hi https://bit.ly/2nUW5Hi"  
[X Link](https://x.com/IntensityInc/status/1031665108861087744)  2018-08-20T22:11Z [---] followers, [--] engagements


"A breakdown on how our lead drug INT230-6 works. https://intensitytherapeutics.com/products/lead-product-int230-6/ https://intensitytherapeutics.com/products/lead-product-int230-6/"  
[X Link](https://x.com/IntensityInc/status/1036754702916964353)  2018-09-03T23:15Z [---] followers, [--] engagements


"Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer see news at http://bit.ly/2VP7WpJ http://bit.ly/2VP7WpJ"  
[X Link](https://x.com/IntensityInc/status/1118503949064114176)  2019-04-17T13:18Z [---] followers, [--] engagements


"Finding improved therapies for triple negative breast #cancer is a critical unmet medical need and we look forward to working closely with the FDA this year to initiate a Phase [--] clinical study for this indication"  
[X Link](https://x.com/IntensityInc/status/1118884155855646722)  2019-04-18T14:29Z [---] followers, [--] engagements


"Intensity Therapeutics will be formally presenting INT230-6 data at The New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium on May 14-15 [----] in New York NY. https://bit.ly/2Q2y6mC https://bit.ly/2Q2y6mC"  
[X Link](https://x.com/IntensityInc/status/1128265155119202304)  2019-05-14T11:45Z [---] followers, [--] engagements


"We are proud to offically collaborate with @Merck. Our lead product INT-230-6 had promising results when tested alone. Now we are aiming to see how it works in combination with their lead product KEYTRUDA (pembrolizumab). https://bit.ly/2RDnpYG https://bit.ly/2RDnpYG"  
[X Link](https://x.com/IntensityInc/status/1143530261411442689)  2019-06-25T14:43Z [---] followers, [--] engagements


"Data from Intensity Therapeutics Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control Abscopal Effects and Immune Response Activity in Patients with Advanced Solid Tumors was selected for an oral podium presentation. https://bit.ly/2WU3s2n https://bit.ly/2WU3s2n"  
[X Link](https://x.com/IntensityInc/status/1192879293421903872)  2019-11-08T18:59Z [---] followers, [--] engagements


"The data being presented at SITC advance our understanding of this new treatment and identify a patient population that seems to derive the most benefit From press release quote by Jacob Thomas MD USC presenter https://bit.ly/2qIYZmU https://bit.ly/2qIYZmU"  
[X Link](https://x.com/IntensityInc/status/1193857309601976320)  2019-11-11T11:45Z [---] followers, [--] engagements


"Congratulations to Intensity and Founder CEO Lew Bender the Company made headlines in Forbes regarding the start ups approach to treating cancer. https://bit.ly/33jBrTx https://bit.ly/33jBrTx"  
[X Link](https://x.com/IntensityInc/status/1199029267176271873)  2019-11-25T18:17Z [---] followers, [--] engagements


"Bender is able to say that INT230-6 has already helped four breast cancer patients who have responded to the new treatment"  
[X Link](https://x.com/IntensityInc/status/1199336682551681024)  2019-11-26T14:38Z [---] followers, [--] engagements


"With the success of our first clinical trials Intensity is excited to begin enrolling patients in phase [--] cohorts with cancers that are difficult to treat and historically nonresponsive to PD1/PDL1 antibodies alone"  
[X Link](https://x.com/IntensityInc/status/1244799943493079041)  2020-03-31T01:33Z [---] followers, [--] engagements


"Intensity is now working with the two leading immunotherapy drugs Yervoy to block CTLA-4 and Keytruda to inhibit the PD-1 receptor to augment and restore T-cell immune response. https://bit.ly/2REl94r https://bit.ly/2REl94r"  
[X Link](https://x.com/IntensityInc/status/1250083565024325632)  2020-04-14T15:28Z [---] followers, [--] engagements


"Intensity Therapeutics Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO [----] https://bit.ly/2ZlUXAd https://bit.ly/2ZlUXAd"  
[X Link](https://x.com/IntensityInc/status/1263212091739000833)  2020-05-20T20:56Z [---] followers, [--] engagements


"Intensity Therapeutics Doses First Patients with Combination of INT230-6 and Mercks Keytruda in Phase [--] studies https://bit.ly/33buPbH https://bit.ly/33buPbH"  
[X Link](https://x.com/IntensityInc/status/1304143614126088192)  2020-09-10T19:44Z [---] followers, [--] engagements


"As we go through our Phase [--] clinical trial with Merck we are excited for the opportunity to treat more people in need of new options"  
[X Link](https://x.com/IntensityInc/status/1304492665132560386)  2020-09-11T18:51Z [---] followers, [--] engagements


"Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibbs Yervoy in a Phase [--] Study https://bit.ly/3kkujiy https://bit.ly/3kkujiy"  
[X Link](https://x.com/IntensityInc/status/1306720830710145024)  2020-09-17T22:24Z [---] followers, [--] engagements


"Intensity is excited for the possibilities with this new phase of clinical trials. We look forward to seeing how our drug INT230-6 synergizes with Yervoy to help #cancer patients"  
[X Link](https://x.com/IntensityInc/status/1307048443521708032)  2020-09-18T20:06Z [---] followers, [--] engagements


"The phase [--] Yervoy combination studies accrue patients that are refractory to standard of care and have high unmet medical need said Ian B. Walters MD Chief Medical Officer"  
[X Link](https://x.com/IntensityInc/status/1308131127576592385)  2020-09-21T19:48Z [---] followers, [--] engagements


"Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC [----] (Abstract 411) https://bit.ly/36mulB4 https://bit.ly/36mulB4"  
[X Link](https://x.com/IntensityInc/status/1326588818028257281)  2020-11-11T18:13Z [---] followers, [--] engagements


"Kaplan Meier analysis shows a 79.1% survival probability estimate at [--] year when dosing a volume of INT230-6 of 50% of the baseline tumor burden; Hazard Ratio is [-----] compared to lower dose"  
[X Link](https://x.com/IntensityInc/status/1327005118277984256)  2020-11-12T21:47Z [---] followers, [--] engagements


"The preliminary data generated supports the hypothesis that dosing a substantial proportion of patients tumor burden with INT230-6 may cause enough tumor killing and immune activation to provide the patient with extended survival - Anthony El-Khoueiry MD"  
[X Link](https://x.com/IntensityInc/status/1327021475644067840)  2020-11-12T22:52Z [---] followers, [--] engagements


"Today Intensity Therapeutics was granted our 3rd US Patent further validating our novel #intratumoral injection approach to treating #cancer. Learn more: #USPatent #SolidTumors https://bit.ly/2Kc18BU https://bit.ly/2Kc18BU"  
[X Link](https://x.com/IntensityInc/status/1349082195286233088)  2021-01-12T19:53Z [---] followers, [--] engagements


"Two days two patents in two countries We've been granted our first Mexico patent titled A Therapeutic Agent And An Intracellular Permeation Enhancing Agent For Use In The Treatment Of Cancer #SolidTumors"  
[X Link](https://x.com/IntensityInc/status/1349737401246248960)  2021-01-14T15:17Z [---] followers, [--] engagements


"This latest pair of patents in Mexico and the US speaks to the potential of our lead asset INT230-6 to bring a paradigm shift in #oncology"  
[X Link](https://x.com/IntensityInc/status/1349810297691922433)  2021-01-14T20:07Z [---] followers, [--] engagements


"Our CEO @LewBender is presenting at the B. Riley Oncology Investor Conference on Wednesday January [--] at 9:30AM EST. Listen to the webcast here: #InvestorConference #Intratumoral https://bit.ly/3nSoxG9 https://bit.ly/3nSoxG9"  
[X Link](https://x.com/IntensityInc/status/1351539440351670274)  2021-01-19T14:38Z [---] followers, [--] engagements


"There are many exciting things in store for us in [----] and we look forward to elaborating on upcoming corporate and clinical milestones"  
[X Link](https://x.com/IntensityInc/status/1351605586467708932)  2021-01-19T19:00Z [---] followers, [--] engagements


"Aqueous #intratumoral injections without Intensitys novel cell penetration enhancing technology are unlikely to be absorbed by the tumor and would be expected to leak out. In contrast INT230-6 when injected into a tumor stays in the tumor"  
[X Link](https://x.com/IntensityInc/status/1358884410335105026)  2021-02-08T21:04Z [---] followers, [--] engagements


"Were excited to announce that we have refreshed the Intensity Therapeutics website today Go check it out: https://intensitytherapeutics.com/ https://intensitytherapeutics.com/"  
[X Link](https://x.com/IntensityInc/status/1359502818122563594)  2021-02-10T14:01Z [---] followers, [--] engagements


"We have partnered with The Ottawa Hospital and The Ontario Institute for Cancer Research to conduct a Phase [--] trial of INT230-6 in patients with early stage #BreastCancer. Read more: @OttawaHospital @OICR_news https://bit.ly/2PliGh2 https://bit.ly/2PliGh2"  
[X Link](https://x.com/IntensityInc/status/1374702644439228421)  2021-03-24T12:40Z [---] followers, [--] engagements


"INT230-6 has the potential to quickly kill tumors during the typical 4-week period from diagnosis to surgery and thus fill a current serious void in cancer treatment"  
[X Link](https://x.com/IntensityInc/status/1374711536627896320)  2021-03-24T13:15Z [---] followers, [--] engagements


"In addition to reducing tumor burdens INT230-6 can induce a patient-specific T-cell response significantly improving patient outlooks and opening new levels of treatment personalization. This study is the next step towards validating a major change in standard of care"  
[X Link](https://x.com/IntensityInc/status/1374720926386810881)  2021-03-24T13:53Z [---] followers, [--] engagements


"Our first #ASCO [----] presentation describes results in patients receiving INT230-6 alone or with pembrolizumab. The second presentation is of INT230-6 in advanced #sarcoma alone and with ipilimumab"  
[X Link](https://x.com/IntensityInc/status/1395382212338540552)  2021-05-20T14:13Z [---] followers, [--] engagements


"Were presenting [--] posters showcasing data that demonstrates INT230-6s efficacy/tolerability in patients with solid tumors as a monotherapy and in combination with checkpoint inhibitors at the [----] @ASCO Annual Meeting (June 4-8). Details here: #ASCO21 https://bit.ly/3yW8G0c https://bit.ly/3yW8G0c"  
[X Link](https://x.com/IntensityInc/status/1400067155274633217)  2021-06-02T12:29Z [---] followers, [--] engagements


"Major @ASCO data highlights include an estimated 62% one-year survival for INT230-6 monotherapy subjects and 88% one-year survival when combined with pembrolizumab. #ASCO21"  
[X Link](https://x.com/IntensityInc/status/1400080421107425280)  2021-06-02T13:22Z [---] followers, [--] engagements


"Use of INT230-6 alone or in combination with ipilimumab showed a median overall survival of [----] months in advanced sarcoma/chordoma patients compared to an expected survival of only [--] to [--] months for these patients in phase 1/2 studies. #ASCO21"  
[X Link](https://x.com/IntensityInc/status/1400088094892871684)  2021-06-02T13:53Z [---] followers, [--] engagements


"These strongly encouraging results in our two @ASCO presentations provide further support of INT230-6s potential in directly killing tumors and shrinking them through abscopal effects. #ASCO21"  
[X Link](https://x.com/IntensityInc/status/1400096235806208005)  2021-06-02T14:25Z [---] followers, [--] engagements


"Yesterday our CEO Lew Bender participated in a fireside chat titled Unprecedented Improvement Upon Intratumoral Injection at the Virtual Healthcare Private Company Forum hosted by Roth Capital. Learn more: #RothConference #InvestorConference https://bit.ly/3qIpB2F https://bit.ly/3qIpB2F"  
[X Link](https://x.com/IntensityInc/status/1409926789795823616)  2021-06-29T17:28Z [---] followers, [--] engagements


"Its an honor to be named Junes Innovator of the Month by Sen. Murphy. We are proud to be recognized for our efforts and to represent Connecticuts emerging biotech sector. A huge thank you to our amazing staff at Westport Read more: @ChrisMurphyCT https://bit.ly/3jwwjqz https://bit.ly/3jwwjqz"  
[X Link](https://x.com/IntensityInc/status/1410341405394968577)  2021-06-30T20:56Z [---] followers, [--] engagements


"Two days [--] news announcements about our [--] presentations at both the annual #CTOS2021 and #sitc2021 (2) meetings. Promising survival data reported in sarcoma a cancer with unmet medical need"  
[X Link](https://x.com/IntensityInc/status/1459532227985956870)  2021-11-13T14:42Z [---] followers, [--] engagements


"Please read today's news release at about our excellent data in #sarcoma reporting increased survival and favorable safety for our drug INT230-6 https://bit.ly/3tdZ4wl https://bit.ly/3tdZ4wl"  
[X Link](https://x.com/IntensityInc/status/1532428357002047491)  2022-06-02T18:26Z [---] followers, [--] engagements


"Our drug INT23-6 data was just discussed and presented at #ASCO22 in live podium discussion session. Dr. Matthew Ingham from Columbia Presbyterian was on the podium to answer questions from the audience"  
[X Link](https://x.com/IntensityInc/status/1533515029324103687)  2022-06-05T18:24Z [---] followers, [--] engagements


"At the same time INT230-6 data alone and combined with Keytruda was just discussed and presented at #ASCO22 in live podium discussion session. Dr. Jacob Thomas from USC was on the podium to answer questions"  
[X Link](https://x.com/IntensityInc/status/1533515748135645187)  2022-06-05T18:27Z [---] followers, [--] engagements


"#DfuseRxSM is our novel proprietary product technology that enables drug compounds to be injected into #solidtumors with high absorption. Our approach is a much more personal dosing approach that also minimizes systemic toxicities. Learn more: $INTS https://bit.ly/3GYhlaF https://bit.ly/3GYhlaF"  
[X Link](https://x.com/anyuser/status/1943302719651090674)  2025-07-10T13:34Z [---] followers, 10.8K engagements


"There are 100+ subtypes of #Sarcoma making it a very tough disease to treat. The current standard of care is highly toxic which makes developing new treatments for this cancer vital for patients. Learn more: $INTS #CureSarcoma #SarcomaAwarenessMonth https://bit.ly/40ipTjJ https://bit.ly/40ipTjJ"  
[X Link](https://x.com/anyuser/status/1945823401589059905)  2025-07-17T12:30Z [---] followers, [----] engagements


"$INTS VP of Clinical Operations Kimberly Guedes brings 30+ years of experience in clinical development and operations. Her expertise includes pre-clinical Phase I-IV trials translational research and multiple drug development disciplines. Learn more: https://bit.ly/4l3PrbU https://bit.ly/4l3PrbU"  
[X Link](https://x.com/anyuser/status/1950184142722785289)  2025-07-29T13:18Z [---] followers, [----] engagements


"$INTS' INT230-6 is a unique #cancertherapy that utilizes a water solution to kill fatty or stromal tumors without harming nearby healthy tissue. Check out the results from #INTS' human #pancreaticcancer in mouse model study and learn more on our website: https://bit.ly/3IT5nQC https://bit.ly/3IT5nQC"  
[X Link](https://x.com/anyuser/status/1950911508092952751)  2025-07-31T13:28Z [---] followers, [----] engagements


"In July [----] $INTS added $6.6 million in gross proceeds ($6.3 million net) by selling [--------] shares of its common stock via its ATM offering at an average price of $0.3323 per share. The new funds provide operating capital into Q3 [----]. Read more: https://bit.ly/45bUVwB https://bit.ly/45bUVwB"  
[X Link](https://x.com/anyuser/status/1952350250813042957)  2025-08-04T12:45Z [---] followers, 27.1K engagements


"#IntensityTherapeutics' mission is to discover develop and commercialize first-in-class cancer drugs to attenuate tumors with minimal side effects and train patients immune systems to fight cancer. Learn about our MOA here: #INTS #CancerResearch $INTS https://bit.ly/47DWm8j https://bit.ly/47DWm8j"  
[X Link](https://x.com/anyuser/status/1958523778259923332)  2025-08-21T13:37Z [---] followers, [----] engagements


"#IntensityTherapeutics Principal Accounting Officer and Controller John Wesolowski CPA MBA is a seasoned finance leader with decades of experience in accounting financial reporting and operational management. Learn more: $INTS https://bit.ly/4krq97F https://bit.ly/4krq97F"  
[X Link](https://x.com/anyuser/status/1960329283945074759)  2025-08-26T13:11Z [---] followers, [----] engagements


"$INTS announces the first Cohort A patient on INT230-6 achieved a pCR in the #INVINCIBLE4 trial. Early safety is favorable though a few patients had mild skin irritation causing a brief enrollment pause to optimize dosing & outcomes. Read more: #TNBC https://bit.ly/4peCQWm https://bit.ly/4peCQWm"  
[X Link](https://x.com/anyuser/status/1965747659232166319)  2025-09-10T12:02Z [---] followers, [----] engagements


"As #BreastCancerAwarenessMonth kicks off #IntensityTherapeutics CEO Lew Bender joined our investment bankers at @MetLifeStadium last Sunday to celebrate the start of breast cancer awareness month and support BC patients during the Giants game. $INTS #BreastCancerAwareness"  
[X Link](https://x.com/anyuser/status/1975542405081223249)  2025-10-07T12:43Z [---] followers, [----] engagements


"#INTS is honored to be shortlisted for @LifeSciEvents' #FierceInnovationAwards: Life Sciences Edition [----] in Drug Delivery This recognizes $INTS's innovation in cancer research & lead candidate INT230-6. All finalists: #FierceLifeSciencesAwards https://bit.ly/4qdpFFO https://bit.ly/4qdpFFO"  
[X Link](https://x.com/anyuser/status/1978804579484537153)  2025-10-16T12:45Z [---] followers, [----] engagements


"Over [------] new invasive breast cancer cases are expected in the U.S. this year according to @theNCI. #IntensityTherapeutics is advancing INT230-6 to activate the immune system for hard-to-treat #breastcancers. Learn more: $INTS #BreastCancerAwareness https://bit.ly/40ipTjJ https://bit.ly/40ipTjJ"  
[X Link](https://x.com/anyuser/status/1981338318370455753)  2025-10-23T12:34Z [---] followers, [----] engagements


"Tomorrow at [--] AM ET $INTS will host a live webinar with authors from @uscnorris & CEO @LewBender on the @eBioMedicine study of INT230-6 in advanced solid tumors. Join to hear key insights from the Phase 1/2 trial. Register: #eBioMedicine @DrElkhoueiry https://bit.ly/3Wu6ObT https://bit.ly/3Wu6ObT"  
[X Link](https://x.com/anyuser/status/1983965361994395816)  2025-10-30T18:32Z [---] followers, [----] engagements


"@medpagetoday featured $INTS in its latest oncology roundup highlighting Phase 1/2 data showing #INT2306achieved 75% disease control & a median OS of [----] months in advanced #solidtumors. Proud to see continued recognition of our progress. Read more: https://bit.ly/4p1XEQi https://bit.ly/4p1XEQi"  
[X Link](https://x.com/anyuser/status/1988602550120259748)  2025-11-12T13:39Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing